Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...
On Oct. 1 and 2, the American Chemical Society held its 21st annual Pharma Leaders Conference, hosted this year at the Merck & Co. campus in Rahway, New Jersey. Leaders in medicinal chemistry from ...
Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...
Merck & Co., Inc. (MRK), headquartered in Rahway, New Jersey, is a major player in healthcare. Specializing in ...
Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYNOTE-689 trial ...
ALAMEDA, Calif. & RAHWAY, N.J., October 14, 2024--Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have ...
Kineta has completed enrollment in the monotherapy cohorts of the Phase 1 VISTA-101 clinical trial. The ongoing Phase 1 study is now enrolling patients into cohorts evaluating KVA12123 in combination ...
Kineta, Inc. (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that its ...
Katharina Geppert, the newly appointed General Director of MSD HH Vietnam Ltd, is dedicated to advancing healthcare and sustainability, in line with the company's mission to improve lives through ...
ALAMEDA, Calif. & RAHWAY, N.J., October 14, 2024--Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have ...
The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in ...